# Author-supplied benchmark construction account

Source: author pasted a team conversation into this thread on 23 October 2026. The underlying messages have no individual timestamps in the supplied copy. This is attributable author-supplied correspondence, not an independently authenticated search log.

## What the correspondence establishes

- Intended strategy: purposive coverage of 15 medical specialties, prioritizing high-ranking journals and highly cited recent 2025–2026 meta-analyses restricted to randomized trials. Author suggested SCImago for journal rankings. Team reported using Europe PMC and citation-ranked candidates; runner-up journals were considered where eligible reviews were scarce.
- Eligibility sought explicit RoB 2 use, extractable trial-level domain judgments, identifiable underlying trials/reports and conventional individually randomized parallel designs. The goal was approximately 100 unique trials with one result candidate each, with a stated range of approximately 75–150.
- Original targets were trial-primary outcomes, with definitions from trial Methods and numerical anchors from abstracts. The team later audited correspondence with the published review labels and changed 43 of 105 assessment targets toward the results assessed in the reviews. This was not a uniformly trial-primary-outcome benchmark at execution.
- Team reported collecting publisher supplements and registry identifiers; final local README documents document conversions, acquisition failures and replacements. Do not imply all possible evidence was available for every trial.
- Final execution instruction explicitly used `assess_outcome` and `assess_values_as_printed`, not `primary_outcome` and `anchor_as_printed`. It requested isolated Sonnet 5.5 Medium runs with a minimal case prompt, no coaching, and exact and binary agreement with published labels (called accuracy in the original request).
- Author's supplied execution request explicitly named Atwine, Haney and Herrmann for exclusion because they **“seem to be unsupported designs.”** This documents an exclusion instruction at the requested-run stage. It does not substantiate Atwine's design classification or establish an independently dated exclusion decision.

## Local corroboration

`rob2-meta-benchmark-set/README-FOR-ALI.md` identifies the revised set as built 3 October 2026, replacing the 29 September set of 106 trials; it records 105 trials from 16 reviews, first-seven table-order sampling with availability replacements, target revisions and identity/deduplication corrections. The inventory contains an additional General Medicine JAMA SGLT2 review alongside the Lancet review. Why this additional review was selected is not stated in the supplied conversation.

Direct CSV check on 23 October: LABEL-TARGETS and OUTCOMES-batch each contain 105 rows; all shared trial rows have identical `assess_outcome` and `assess_values_as_printed` values. In the full set, collapsed target-status categories are 77 same, 9 partly, 9 different and 10 unknown; “same” includes inferred and multi-outcome labels. Among the 102 included trials, these are 76, 7, 9 and 10. These counts describe target correspondence, not performance subgroups.

## Reporting implications and unresolved facts

Describe a purposively assembled, cross-specialty benchmark informed by journal standing, citation counts and usable RoB 2 labels. Do not certify that each selected review was the highest cited eligible review in the highest ranked journal without search/ranking records. Do not call the selection exhaustive, systematic or representative. The correspondence's concern about all-Low reviews does not show they were removed; the final benchmark retains Low-heavy reviews.

Author follow-up: the author does not recall search dates/ranking records or why the second General Medicine review was added. Report the purposive strategy without certified ranking claims; these details remain unrecovered, not presumed absent historically. The author states that Atwine's stored classification is wrong and instructs treating its design as unsupported. Retain its exclusion on that author-confirmed basis. No specific alternative design subtype or supporting rationale has been supplied, so do not invent one or claim independent design verification. Expert procedures, prompt-development overlap and endpoint-specification chronology are not answered by this correspondence.

## Candidate Methods wording — for integration after interview

We assembled a purposive benchmark across 15 medical specialties, seeking recent meta-analyses of randomized trials in high-ranking journals that provided extractable trial-level RoB 2 judgments. The selection team reported searching Europe PMC for 2025–2026 reviews and prioritizing highly cited eligible reviews, with alternative journals considered where suitable reviews were unavailable. The final source set comprised 16 reviews. Within reviews, trials were selected in table order, taking up to seven obtainable eligible trials and replacing unavailable reports with the next eligible trial; duplicate reports of the same randomized trial were removed.

Candidate results initially followed each trial's primary outcome. Before the reported benchmark runs, the targets were reviewed against the results underlying the published RoB 2 labels and revised where needed. The final prompts used the specified assessment outcome and numerical result in the revised target ledger. Correspondence with published labels remained partial, inferred, different or indeterminate for some targets. The revised source set contained 105 trials; three trials designated as unsupported designs were excluded from the analysis, leaving 102.

Editorial provenance for the last sentence: unsupported designation is confirmed by the author; this memo does not independently establish Atwine's specific design restriction.
